Solutions

Fulfill post-market regulartory requirements and assess long-term product safety more efficiently with real-time data.

Truveta enables life sciences companies to:

• Meet regulatory evidence standards faster and at lower cost by eliminating the need for expensive and long-running registries
• Quickly assess the validity of potential safety signals with real-time data
• Conduct studies assessing the long-term, real-world safety of different treatments with access to complete medical records, including notes and images

Assessing the safety of novel interventions

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

 Read the research

Evaluate clinical- and cost-effectiveness to differentiate products using real-world data from 30 health systems.

Truveta enables life sciences companies to:

• Assess the clinical- and cost-effectiveness of therapies to inform access and reimbursement decisions
• Generate scientific evidence on comparative effectiveness and long-term outcomes to connect the right patients to the right therapies
• Analyze real-world treatment pathways and healthcare resource utilization patterns to inform access and engagement programs

Comparing real-world treatment outcomes

Hazard of cardiovascular events associated with SGLT2i vs metformin

• Monitor disease trends and vaccine safety with daily-updated data
• Study maternal and child health with access to more than 1 million mother-child pairs
• Analyze the impact of more than 45 SDOH variables on healthcare access and outcomes
• Gauge the impact of policies on health outcomes, healthcare utilization, costs, and population health with complete EHR data linked to SDOH, mortality, and claims data

Respiratory virus-associated hospitalizations (from monitoring report)

Rate of weekly respiratory virus-associated hospitalizations compared to all hospitalizations since October 2019

 Read the report

Validate trial design and supplement trial data with real-world arms.

Truveta enables life sciences companies to:

• Build and analyze precise populations with complete data for 100M+ patients
• De-risk clinical programs with dynamic, real-time analytics 
• Generate evidence for real-world control arms using regulatory-grade data

Testing I/E criteria to de-risk clinical programs

Sample heart failure population with inclusion/exclusion criteria applied

 Read the webinar recap

Real-time dashboard showing TAVR volumes, access by cohort, and adverse events  Monitor patient outcomes and benchmark to real-time, nationally representative EHR data.

Truveta enables healthcare organizations to:

• Deliver more equitable, high-quality care by identifying disparities and gaps in care
• Guide evidence-based decisions by linking treatment patterns to outcomes
• Assess variations in care quality to support value-based care programs

Tracking procedure utilization and outcomes over time

Real-time dashboard showing TAVR volumes, access by cohort, and adverse events

Monitor and ensure patient access to therapies using real-time EHR data. 

Truveta enables life sciences companies to:

• Assess product utilization and market share trends
• Generate compelling evidence of real-world effectiveness and economic value to inform coverage and reimbursement decisions
• Monitor and remediate the impact of potential supply chain shortages 

Assessing the impact of drug shortages

Rate of amphetamine/dextroamphetamine prescription fills per eligible population, stratified by age

Read the research

Train AI models for discovery and product enhancement with complete and representative EHR data. 

Truveta enables life sciences companies to:

• Identify patient subgroups most likely to respond to a therapy or experience specific medical events
• Discover product enhancement or innovation opportunities using AI trained on medical records

Exploring the association between heart failure and medication use

Population clustering to facilitate drug discovery